Početna › Atopijski dermatitis (ekcem) › Michigan
Kliničke studije za Atopijski dermatitis (ekcem) u državi Michigan
14 studija za Atopijski dermatitis (ekcem) traži sudionike na lokacijama u državi Michigan.
Gradovi u državi Michigan
Službeni tekst studije (engleski)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017, Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042, Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052, Bay City
- i još 3
U tijeku regrutacijaOpažajna studija
Od 12 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Troy
U tijeku regrutacijaFaza 2
Od 18 do 100 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Auburn Hills
- Enveda Investigative Site, Bay City
- Enveda Investigative Site, Clinton Township
- i još 1
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Detroit
- Investigational Site, Troy
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Derm Research Institute, PLC, Caledonia
U tijeku regrutacijaOpažajna studija
Od 12 do 89 godina · Oba spola · Ažurirano 15. ruj 2026. · NCT07645820A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Revival Research Institute, LLC, Troy
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07223697FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Revival Research Institute, LLC, Troy
U tijeku regrutacijaFaza 1Zdravi dobrovoljci dobrodošli
Od 18 do 70 godina · Oba spola · Ažurirano 22. srp 2026. · NCT06564389A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Waterford
U tijeku regrutacijaFaza 3
6 Months – 11 Years · Oba spola · Ažurirano 7. srp 2026. · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Henry Ford Medical Center - New Center One /ID# 263522, Detroit
U tijeku regrutacijaFaza 3
Od 18 do 63 godina · Oba spola · Ažurirano 6. srp 2026. · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Michigan Center for Research Company, Clarkston
- MI Skin Innovations, Northville
- Revival Research Institute LLC, Troy
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 4. svi 2026. · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7066, Auburn Hills
- Galderma Investigational Site 7071, Caledonia
- Galderma Investigational Site 7108, Grandville
- i još 1
U tijeku regrutacijaOpažajna studija
Od 12 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT06988605Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- University of Michigan, Ann Arbor
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 10 do 55 godina · Oba spola · Ažurirano 25. stu 2025. · NCT06300697Ethnic Differences in Mechanisms of Action of Dupilumab
- University of Michigan, Ann Arbor
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 6. stu 2025. · NCT05268107A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 24. sij 2025. · NCT06524635Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.